Kellner Capital’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Kellner Capital’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$861K	Buy	+20,300	New	+$583K	1.55%	15

Other funds holding CERE

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Kellner Capital's CERE Position: Q4 2023 in Review

Kellner Capital opened a new position in Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q4 2023: 20,300 shares worth $861K. The stake represents 1.55% of the portfolio and ranks #15 among its holdings.

195 funds tracked by Wall St. Rank hold CERE as of Q4 2023.

Kellner Capital held 20,300 shares of Cerevel Therapeutics Holdings, Inc. Common Stock worth $861K as of Q4 2023.
Cerevel Therapeutics Holdings, Inc. Common Stock was a new Kellner Capital position in Q4 2023.
Cerevel Therapeutics Holdings, Inc. Common Stock made up 1.55% of Kellner Capital's portfolio in Q4 2023, its #15 holding.
195 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q4 2023.

Based on Kellner Capital's 13F filing for Q4 2023, filed 7 Feb 2024.